Mariner LLC Boosts Stock Holdings in Stryker Corporation $SYK

Mariner LLC raised its holdings in Stryker Corporation (NYSE:SYK) by 2.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 605,092 shares of the medical technology company’s stock after acquiring an additional 13,209 shares during the quarter. Mariner LLC owned 0.16% of Stryker worth $223,684,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of SYK. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new position in Stryker in the second quarter valued at $205,000. Cetera Investment Advisers increased its stake in Stryker by 2.2% in the second quarter. Cetera Investment Advisers now owns 98,966 shares of the medical technology company’s stock valued at $39,154,000 after purchasing an additional 2,169 shares during the last quarter. Intech Investment Management LLC grew its holdings in Stryker by 8.7% in the 2nd quarter. Intech Investment Management LLC now owns 5,977 shares of the medical technology company’s stock valued at $2,365,000 after buying an additional 477 shares during the period. Finally, Avantax Advisory Services Inc. grew its holdings in Stryker by 6.2% in the 2nd quarter. Avantax Advisory Services Inc. now owns 23,629 shares of the medical technology company’s stock valued at $9,348,000 after buying an additional 1,387 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 3.9%

SYK stock opened at $349.89 on Tuesday. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The firm has a 50 day simple moving average of $365.22 and a 200-day simple moving average of $367.06. The company has a market capitalization of $133.90 billion, a P/E ratio of 41.65, a PEG ratio of 1.97 and a beta of 0.85. Stryker Corporation has a twelve month low of $328.23 and a twelve month high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $4.01 earnings per share. On average, equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on SYK shares. The Goldman Sachs Group set a $399.00 target price on shares of Stryker in a research report on Friday, January 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a report on Monday, December 22nd. Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price objective for the company in a research note on Friday, December 19th. BTIG Research increased their target price on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Finally, William Blair reiterated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $428.61.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.20% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.